骨质疏松新药雷奈酸锶研究进展

被引：2

作者：

张志宏 ^{[1
,2
]}

沈舜义 ^{[1
,2
]}

机构：

[1] 中国医药工业研究总院

[2] 上海医药工业研究院

来源：

世界临床药物 | 2011年 / 32卷 / 11期

关键词：

雷奈酸锶; 骨质疏松症; 绝经后骨质疏松症;

D O I：

暂无

中图分类号：

R580 [];

学科分类号：

1002 ; 100201 ;

摘要：

骨质疏松症是一种以骨量减少,骨组织破坏为特征而导致骨脆性增加并易于骨折的全身性骨骼疾病。本文从作用机制出发,综述首个开发上市的具有抑制破骨细胞吸收和促进骨形成双重作用的新药雷奈酸锶,评价其用于治疗绝经后骨质疏松症的临床安全性和有效性。

引用

页码：641 / 645

页数：5

共 20 条

[1] A new insight into the dissociating effect of strontium on bone resorption and formation [J].

Braux, Julien ;

Velard, Frederic ;

Guillaume, Christine ;

Bouthors, Sylvie ;

Jallot, Edouard ;

Nedelec, Jean-Marie ;

Laurent-Maquin, Dominique ;

Laquerriere, Patrice .

ACTA BIOMATERIALIA, 2011, 7 (06) :2593-2603

[2]

Ranélate de strontium (Protelos ? ) : effets indésirables rapportés en France[J] . Annie-Pierre Jonville-Bera,Elisabeth Autret-Leca.La Presse Medicale . 2011 (10)

[3]

Treatment of osteoporosis: recognizing and managing cutaneous adverse reactions and drug-induced hypersensitivity[J] . P. Musette,M. L. Brandi,P. Cacoub,J. M. Kaufman,R. Rizzoli,J.-Y. Reginster.Osteoporosis International . 2010 (5)

[4]

Osteoporosis and venous thromboembolism: a retrospective cohort study in the UK General Practice Research Database[J] . G. Breart,C. Cooper,O. Meyer,C. Speirs,N. Deltour,J. Y. Reginster.Osteoporosis International . 2010 (7)

[5]

Long-term treatment of postmenopausal osteoporosis with strontium ranelate: Results at 8 years[J] . J.Y. Reginster,O. Bruyère,A. Sawicki,A. Roces-Varela,P. Fardellone,A. Roberts,J.P. Devogelaer.Bone . 2009 (6)

[6] Efficacy and safety of 2 g/day of strontium ranelate in Asian women with postmenopausal osteoporosis [J].

Liu, Jian-Min ;

Kung, Annie Wai-chee ;

Pheng, Chan Siew ;

Zhu, Han-Min ;

Zhang, Zhen-Lin ;

Wu, Yi-Yong ;

Xu, Ling ;

Meng, Xun-Wu ;

Huang, Min-Li ;

Chung, Leung Ping ;

Hussain, Nik Hazlina Nik ;

Sufian, Seri Suniza ;

Chen, Jia-Lun .

BONE, 2009, 45 (03) :460-465

[7] Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis [J].

Meunier, P. J. ;

Roux, C. ;

Ortolani, S. ;

Diaz-Curiel, M. ;

Compston, J. ;

Marquis, P. ;

Cormier, C. ;

Isaia, G. ;

Badurski, J. ;

Wark, J. D. ;

Collette, J. ;

Reginster, J. Y. .

OSTEOPOROSIS INTERNATIONAL, 2009, 20 (10) :1663-1673

[8] Strontium ranelate treatment of human primary osteoblasts promotes an osteocyte-like phenotype while eliciting an osteoprotegerin response [J].

Atkins, G. J. ;

Welldon, K. J. ;

Halbout, P. ;

Findlay, D. M. .

OSTEOPOROSIS INTERNATIONAL, 2009, 20 (04) :653-664

[9]

Effects of long‐term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five‐year, randomized, placebo‐controlled trial[J] . Jean‐YvesReginster,DieterFelsenberg,StevenBoonen,AdolfoDiez‐Perez,ReneRizzoli,Maria‐LuisaBrandi,Tim D.Spector,KimBrixen,StefanGoemaere,CatherineCormier,AdamBalogh,Pierre D.Delmas,Pierre J.Meunier.Arthritis & Rheumatism . 2008 (6)

[10]

Addressing and meeting the needs of osteoporotic patients with strontium ranelate: a review[J] . Steven Boonen.Current Opinion in Rheumatology . 2006

← 1 2 →